Table Info

Table 1.

Baseline characteristics and current state of patients

#	Gender	Age (years)	Failed DSZ w/o OMZ	Casein sIgE	α-LA sIgE	β-LG sIgE	OVM sIgE	OVA sIgE	Courses of OMZ	Current OMZ	Current tolerance
1	M	8	No	15	7	0	-	-	1	Yes	No
2	F	4.3	Yes	34	9	10	-	-	1	Yes	No
3	M	5.4	No	2,040	84	294	-	-	1	Yes	Yes
4	F	3.7	Yes	1	7	2	-	-	1	No	Yes
5	M	16.6	No	58	11	18	-	-	1	No	Yes
6	F	3.7	Yes	64	21	9	-	-	1	No	Yes
7	M	4.1	No	128	34	14	-	-	1	No	Yes
8	F	4.1	Yes	308	43	12	-	-	1	No	Yes
9	M	6	No	869	41	12	-	-	1	No	Yes
10	M	7.5	Yes	-	-	-	4	2	1	No	Yes
11	M	6.2	Yes	-	-	-	> 100	78	1	No	Yes
12	F	8.6	Yes	-	-	-	3	1	1	No	No
13	F	4	Yes	75	28	28	-	-	2	No	Yes
14	M	3.5	Yes	833	-	-	-	-	2	No	Yes
15	F	10.7	No	-	-	-	340	690	2	No	Yes
16	M	10.6	No	-	-	-	95	335	2	No	Yes
17	F	10.1	Yes	-	-	-	135	155	2	No	Yes
18	M	6.3	No	-	-	-	48	9	2	No	Yes
19	F	8.8	Yes	-	-	-	> 100	14	2	No	No
20	F	10.8	Yes	-	-	-	18	32	2	No	No
21	M	6.7	Yes	-	-	-	30	32	2	No	No

sIgE in kUA/L. M: male; F: female; w/o: without; α-LA: α-lactalbumin; β-LG: β-lactoglobulin; OVA: ovalbumin. -: not applicable. Diluted serum was used, when enough sample was available, to measure sIgE > 100 kUA/L

Declarations

Author contributions

AM: Conceptualization, Formal analysis, Investigation, Supervision, Visualization, Writing—original draft, Writing—review & editing. DTJ: Data curation, Formal analysis, Supervision, Visualization, Writing—review & editing. BF, MPS, LI, EB, and MN: Data curation, Investigation, Writing—review & editing. SU: Conceptualization, Investigation, Supervision, Writing—review & editing. AN: Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The research in this manuscript complies with the Declaration of Helsinki. The study was approved by the Institutional Ethics Committee of the Health Research Institute Hospital La Fe (no. 2017/0435).

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Datasets are available from the corresponding author (amazon@comv.es) on reasonable request.

Funding

Not applicable.

Copyright

References

Kim M, Lee JY, Yang HK, Won HJ, Kim K, Kim J, et al. The natural course of immediate-type cow’s milk and egg allergies in children. Int Arch Allergy Immunol. 2020;181:103–10. [DOI] [PubMed]

Gernez Y, Nowak-Węgrzyn A. Immunotherapy for food allergy: Are we there yet? J Allergy Clin Immunol Pract. 2017;5:250–72. Erratum in: J Allergy Clin Immunol Pract. 2017;5:1167. [DOI] [PubMed]

Martorell Calatayud C, Muriel García A, Martorell Aragonés A, De La Hoz Caballer B. Safety and efficacy profile and immunological changes associated with oral immunotherapy for IgE-mediated cow’s milk allergy in children: systematic review and meta-analysis. J Investig Allergol Clin Immunol. 2014;24:298–307. [PubMed]

Dantzer JA, Wood RA. The use of omalizumab in allergen immunotherapy. Clin Exp Allergy. 2018;48:232–40. [DOI] [PubMed]

Lin C, Lee IT, Sampath V, Dinakar C, DeKruyff RH, Schneider LC, et al. Combining anti-IgE with oral immunotherapy. Pediatr Allergy Immunol. 2017;28:619–27. [DOI] [PubMed]

Ibáñez-Sandín MD, Escudero C, Candón Morillo R, Lasa EM, Marchán-Martín E, Sánchez-García S, et al.; OmaBASE task force (Pediatric Allergy Committee; Spanish Society of Allergy and Clinical Immunology). Oral immunotherapy in severe cow’s milk allergic patients treated with omalizumab: real life survey from a Spanish registry. Pediatr Allergy Immunol. 2021;32:1287–95. [DOI] [PubMed]

Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol. 2014;25:717–9. [DOI] [PubMed]

Martorell A, Alonso E, Echeverría L, Escudero C, García-Rodríguez R, Blasco C, et al.; Expert panel selected from members of the Spanish Society of Pediatric Allergology, Asthma and Clinical Immunology (SEICAP) and the Spanish Society of Allergology and Clinical Immunology (SEAIC). Oral immunotherapy for food allergy: a Spanish guideline. Immunotherapy egg and milk Spanish guide (items guide). Part I: cow milk and egg oral immunotherapy: introduction, methodology, rationale, current state, indications contraindications and oral immunotherapy build-up phase. Allergol Immunopathol (Madr). 2017;45:393–404. [DOI] [PubMed]

Martorell A, Alonso E, Echeverría L, Escudero C, García-Rodríguez R, Blasco C, et al.; Expert panel selected from members of the Spanish Society of Pediatric Allergology, Asthma and Clinical Immunology (SEICAP) and the Spanish Society of Allergology and Clinical Immunology (SEAIC). Oral immunotherapy for food allergy: a Spanish guideline. Egg and milk immunotherapy Spanish guide (items guide). Part 2: maintenance phase of cow milk (CM) and egg oral immunotherapy (OIT), special treatment dosing schedules. Models of dosing schedules of OIT with CM and egg. Allergol Immunopathol (Madr). 2017;45:508–18. [DOI] [PubMed]

10.

Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137:1103–10.E11. [DOI] [PubMed] [PMC]

11.

Lombardi C, Canonica GW, Passlacqua G. Allergen immunotherapy as add-on to biologic agents. Curr Opin Allergy Clin Immunol. 2018;18:502–8. [DOI] [PubMed]

12.

Martorell-Calatayud C, Michavila-Gómez A, Martorell-Aragonés A, Molini-Menchón N, Cerdá-Mir JC, Félix-Toledo R, et al. Anti-IgE-assisted desensitization to egg and cow’s milk in patients refractory to conventional oral immunotherapy. Pediatr Allergy Immunol. 2016;27:544–6. [DOI] [PubMed]

13.

Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab. Mucosal Immunol. 2012;5:267–76. [DOI] [PubMed] [PMC]

14.

García-Lirio E, Gonzalez Diaz C, Gonzalez Hermosa A, Gamboa P, Aranguren R, Sanz ML. Oral immunotherapy with egg and milk: changes in peripheral serum cytokines are not predictive factors for severe adverse reactions or for the final report. J Investig Allergol Clin Immunol. 2018;28:24–8. [DOI] [PubMed]

15.

Wawrzyniak M, O’Mahony L, Akdis M. Role of regulatory cells in oral tolerance. Allergy Asthma Immunol Res. 2017;9:107–15. [DOI] [PubMed] [PMC]

16.

Perezábad L, Reche M, Valbuena T, López-Fandiño R, Molina E, López-Expósito I. Oral food desensitization in children with IgE-mediated cow’s milk allergy: immunological changes underlying desensitization. Allergy Asthma Immunol Res. 2017;9:35–42. [DOI] [PubMed] [PMC]

17.

Vilar LK, Araújo FA, Santos TP, Menezes TT, Cheik MF, Segundo GRS. Baked tolerance in cow’s milk allergy: quite frequent, hard to predict! Int Arch Allergy Immunol. 2021;182:319–23. [DOI] [PubMed]

18.

Peters RL, Krawiec M, Koplin JJ, Santos AF. Update on food allergy. Pediatr Allergy Immunol. 2021;32:647–57. [DOI] [PubMed] [PMC]